Online Report 2021
Video CEO

Addition to the Executive Committee
With effect from 1 January, Irene Wosgien joins Siegfried Group’s Executive Committee as Chief Operating Officer Drug Substances. 

Jan – Feb

Finalization of acquisition
Siegfried successfully finalizes the acquisition of two pharmaceutical production sites from Novartis in Spain.

Jan – Feb

Virtual Annual
General Meeting
Siegfried again carries out its annual general meeting in virtual format and decides to distribute CHF 3.00 per registered share. 

March – Apr

Support vaccine filling 
for Novavax
Siegfried announces support for Novavax in commercial filling of its innovative coronavirus vaccine candidate NVX-CoV2373. 


May – Jun

Filling BioNTech vaccine
Commercial filling of the innovative mRNA ­coronavirus vaccine BNT162b2 (“Comirnaty”) for the German pharmaceutical company BioNTech at the Hameln site was successfully started on schedule.  


July – Aug

Center of Excellence
Start of establishing the planned Center of Excellence for high-quality development services in the area of Drug Products plus extensive investment in laboratories and pilot plants at both Spanish sites, Barberà del Vallès and El Masnou. 

July – Aug

Addition to Executive Committee

With effect from 1 October 2021, Marcel ­Imwinkelried is appointed Chief Operating Officer of Technical Operations Drug Products and joins the Executive Committee of the Siegfried Group.


Sep – Oct

UN Global Compact
Siegfried announces its membership in Global Compact Network Switzerland & Liechtenstein.

Nov – Dec
Downloads 2021
Downloads 2021
Downloads 2021
Downloads 2021
Intro Kennzahlen 2021
Kennzahlen 2021